AstraZeneca
rare disease highlights advancing expansion of in nephrology data supports initiation of potential phase trial mean spot weeks rapid complete and sustained complement inhibition at week potential disease modifying reduction in proteinuria significant unmet need for patients on | AstraZeneca
Company
Deck Type
Deck date
November 2023
Slide
29 of 45
Other recent decks by AstraZeneca
Results
February 2024
Investor Conference
January 2024
Results
July 2023
Investor Event
June 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io